BioLargo, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced total revenue was USD 464,000 compared to USD 418,000 a year ago. Operating loss was USD 1.702 million compared to USD 2.005 million a year ago. Net loss was USD 1.622 million compared to USD 2.426 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago. Diluted loss per share from continuing operations was USD 0.01 compared to USD 0.01 a year ago. For the half year, total revenue was USD 1.035 million compared to USD 856,000 a year ago. Operating loss was USD 3.560 million compared to USD 3.706 million a year ago. Net loss was USD 3.253 million compared to USD 4.699 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.03 a year ago. Diluted loss per share from continuing operations was USD 0.02 compared to USD 0.03 a year ago.